Arch Endocrinol Metab (2019) 63:58291
An oral GLP-1 receptor agonist, orfoglipron, has demonstrated promising results in phase II trials for obesity, with weight loss ranging from 9.4% to 14.7% over 36 weeks, comparable to other injectable GLP-1 analogues (142)
Semaglutida reduce la glucosa en sangre a travs de un mecanismo en el que estimula la secrecin de insulina y disminuye la secrecin de glucagn, ambos de manera dependiente de la glucosa
It typically takes 45 weeks to reach steady levels in the body after starting the medication
GLP-1 Injections and Lifestyle GLP-1 injections may be part of a broader strategy that includes: Balanced nutrition Regular movement Sleep and stress management Routine check-ins with your provider GLP-1 medications are not a standalone solution, and their effectiveness may depend on how theyre incorporated into a full treatment plan
Employers should cover all evidence-based obesity care options, including drugs, nutrition therapy, behavioral health services and surgery, the groups say